Burow Kristina — SEC Form 4 filings
SEC reporting owner CIK 1569248. 26 Form 4 filings on record with FilingPulse; latest filed 2026-07-06.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2024-02-12 to 2026-07-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 9 filings — 15,224,493 shares, $140,499,943 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 3 filings — 24,453 shares, $364,414 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 67.
- Largest priced transaction: purchase of 1,432,224 shares @ $18.00 ($25,780,032) in Metsera, Inc., filed 2025-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Metsera, Inc. (MTSR) | Director | 3 | 2 legs · 2,222,222 sh · $39,999,996 | — | 16 |
| Prime Medicine, Inc. (PRME) | 10% owner | 2 | 2 legs · 6,230,300 sh · $29,999,990 | — | — |
| Kardigan, Inc. (KARD) | Director, 10% owner | 2 | 1 leg · 1,250,000 sh · $20,000,000 | — | 4 |
| Seaport Therapeutics, Inc. (SPTX) | 10% owner | 1 | 1 leg · 1,100,000 sh · $19,800,000 | — | 4 |
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 1 | 1 leg · 488,090 sh · $12,499,985 | — | — |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 1 | 3 legs · 1,818,181 sh · $9,999,996 | — | — |
| Neumora Therapeutics, Inc. (NMRA) | Director, 10% owner | 5 | 1 leg · 1,915,700 sh · $4,999,977 | — | 12 |
| Boundless Bio, Inc. (BOLD) | 10% owner | 4 | 2 legs · 200,000 sh · $3,200,000 | 1 leg · 16,000 sh · $39,840 | 14 |
| Scholar Rock Holding Corp (SRRK) | Director | 6 | — | 4 legs · 8,453 sh · $324,574 | 14 |
| Rapport Therapeutics, Inc. (RAPP) | 10% owner | 1 | — | — | 3 |
Form 4 filings — Burow Kristina
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-06 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN | Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 2,105 @ $53.49 · Sale (S): 948 @ $54.28 | EDGAR |
| 2026-06-24 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Purchase (P): 1,250,000 @ $16 | EDGAR |
| 2026-06-22 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative) | EDGAR |
| 2026-06-08 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 6,839 @ $0 · Grant/award (A): 4,310 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | Scholar Rock Holding Corp (SRRK) | Option exercise (M): 7,800 @ $26.78 · Option exercise (M): 28,000 @ $4.75 · Option exercise (M): 36,000 @ $9.11 · Option exercise (M): 18,000 @ $8.36 · Option exercise (M): 7,800 (derivative) @ $0 · Option exercise (M): 28,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2025-11-13 | 4 | Metsera, Inc. (MTSR) | Disposition to issuer (D): 2,688 · Disposition to issuer (D): 17,070,904 · Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 7,523,682 · Disposition to issuer (D): 8,313,680 · Grant/award (A): 2,688 (derivative) · +2 more | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-06-23 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 46,455 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 46,455 (derivative) · Grant/award (A): 28,571 (derivative) · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 1,000 @ $29.24 · Sale (S): 4,400 @ $29.83 | EDGAR |
| 2025-05-23 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 7,632 @ $0 · Grant/award (A): 9,206 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Metsera, Inc. (MTSR) | Grant/award (A): 16,125 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 46,455 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 46,455 (derivative) · Grant/award (A): 28,571 (derivative) | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) | Conversion (C): 16,006,949 · Purchase (P): 1,432,224 @ $18 · Conversion (C): 7,523,682 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 more | EDGAR |
| 2024-07-01 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 13,500 @ $0 · Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 20,100 @ $0 · Grant/award (A): 28,571 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) | Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 more | EDGAR |
| 2024-03-29 | 4 | Boundless Bio, Inc. (BOLD) | Grant/award (A): 26,438 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, GILLIS STEVEN | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1569248 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →